Duncan Barbara Gayle 4

4 · Atea Pharmaceuticals, Inc. · Filed Jun 24, 2025

Form 4

Period: 2025-06-20

Director

Transactions

Exercise/Conversion
Common Stock
2025-06-20+29,600→ 62,750 total
Award
Stock Option (Right to Buy)
2025-06-20+41,200→ 41,200 total
Exercise: $3.25Exp: 2035-06-19→ Common Stock (41,200 underlying)
Award
Restricted Stock Units
2025-06-20+29,600→ 29,600 total
→ Common Stock (29,600 underlying)
Exercise/Conversion
Restricted Stock Units
2025-06-20−29,600→ 0 total
→ Common Stock (29,600 underlying)

Footnotes (4)

[F1]Restricted stock units convert into common stock on a one-for-one basis.
[F2]The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
[F3]The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.
[F4]The restricted stock units vested in full on June 20, 2025.

Documents

1 file